Skip to Main Content

Paper Details

Determinants of Neutralizing Antibody Response After SARS CoV-2 Vaccination in Patients With Myeloma.
Journal of Clinical Oncology
29
2022
B, B-cell malignancies, B1., B1.617, COVID-19, MM, Myeloma, Patients, RBD, SARS, SARS CoV, SARS CoV-2, SARS CoV-2 spike receptor-binding domain, antispike RBD antibodies, immunocompromised, mRNA1273 vaccine, multiple myeloma, myeloma, neutralizing, patients, viral nucleocapsid
Author NameAffiliation
Craig C HofmeisterEmory University
Craig C HofmeisterWinship Cancer Institute
Sagar LonialEmory University
Sagar LonialWinship Cancer Institute
Rafi AhmedWinship Cancer Institute
Rafi AhmedEmory University
Mehul S SutharEmory University
Mehul S Suthar
Mehul S SutharCenter for Childhood Infections and Vaccines of Children's Healthcare of Atlanta, Emory University School of Medicine
  • 1 - 9

Datasets

Release 1.2